Navigation Links
MiMedx Announces Record Second Quarter Results
Date:7/31/2013

MARIETTA, Ga., July 31, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2013.

Highlights of second quarter 2013 results include:

  • Revenue met or exceeded  forecast for 7th consecutive quarter
  • Revenue increased more than 175% over second quarter of 2012
  • Six-month revenue increased more than 190% over first half of 2012
  • Sixth consecutive quarter of positive Adjusted EBITDA
  • Gross Margins improved by 7% over second quarter of 2012
  • Six month gross margins improved 8% over prior year
  • Company reiterates third quarter and full year 2013 guidance
  • Second Quarter 2013 Results
    The Company recorded record revenue of $13.51 million for the quarter ended June 30, 2013, an increase of more than 175% over second quarter of 2012 revenue of $4.88 million. The Company's second quarter gross margins were 84% as compared to gross margins of 77% in the second quarter of last year.  Earnings before interest, taxes, depreciation, amortization and share based compensation, non-cash impairment and earn out liability charges (Adjusted EBITDA) for the second quarter of 2013 were $1.17 million, a $242,000  or 26% improvement as compared to the Adjusted EBITDA  of $923,000 for the second quarter of 2012. The Net Loss for the second quarter of 2013 was $757,000 as compared to the Net Loss of $744,000 in the second quarter of the prior year.

    For the six months ended June 30, 2013, the Company recorded record revenue of $25.07 million, an increase of more than 190% over revenue of $8.59 million recorded for the first six months
    '/>"/>

    SOURCE MiMedx Group, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
    2. MiMedx To Exceed High End Of Second Quarter Guidance
    3. MiMedx to Ring NASDAQ Stock Market Opening Bell
    4. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
    5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
    6. MiMedx Announces Record First Quarter 2013 Results
    7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
    8. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
    9. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
    10. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
    11. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... , Sept. 23, 2014 ... of the biomaterial family and are increasingly becoming ... body fluids and tissues without having a negative ... used as tissue replacement and tissue repair materials ... materials such as ceramics, glass, glass-ceramics, and composites. ...
    (Date:9/23/2014)... Kamal Rashid , PhD, director of ... Center (BETC) and research professor of biology and biotechnology ... an international two-day event focused on biomanufacturing set for ... the event will bring together leaders of companies from ... and produce human therapeutics. “The growth curve for biomanufacturing ...
    (Date:9/23/2014)... 2014 This is a professional ... the Phenolic Resin industry in Global and China.The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
    (Date:9/23/2014)... de Reuil, France (PRWEB) September 23, 2014 ... to protection of laboratory personnel since 1968 and Burdinola, ... the development of a new filtered fume hood. ... above their laboratory fume hood, Burdinola will now offer ... for filtering a wide range of chemicals, best-in-class detection ...
    Breaking Biology Technology:Global Bioactive Material Market 2014-2018 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2
    ... , , , ... (Medical College), a private medical school with more than 1,100 physicians, ... (SRM) solution to track, manage and report adverse and near-miss events, ... Event Manager (EM) and Claims Manager (CM) modules, part of the ...
    ... ... Room To Share Due Diligence Documents , ... Los Gatos, CA (PRWEB) September 16, 2009 -- Pandesa ... a number of pharmaceutical, biopharmaceutical and biotech research and development companies worldwide, to securely ...
    ... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, ... licensee for perifosine in the North American market, has ... Food and Drug Administration (FDA) for the treatment of ...
    Cached Biology Technology:The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 3AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3
    (Date:9/23/2014)... Scientists have scoured cow rumens and termite guts for ... for the production of next-generation biofuels, but some of ... human lower intestine, researchers report. , Their study ... Academy of Sciences , is the first to use ... the human gut can digest fiber, breaking it down ...
    (Date:9/23/2014)... could be as good for your mental as your ... by the University of Warwick,s Medical School using data ... BMJ Open focused on mental wellbeing and ... associated with an individual,s fruit and vegetable consumption. , ... or more portions of fruit and vegetables a day, ...
    (Date:9/23/2014)... organisms, including humans, have parasitic DNA fragments called "jumping ... instructions in the process. And that phenomenon can result ... the University of Rochester now report that the "jumping ... when a multi-function protein stops keeping them in check ... In a study published today in Nature Communications ...
    Breaking Biology News(10 mins):Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3Eating five a day may keep the blues away 2A multi-function protein is key to stopping genomic parasites from 'jumping' 2
    ... therapies similar to those used for HIV patients may be the ... the University of Leeds. A study of a protein called ... the protein between virus strains - known as genotypes - ... function. The p7 protein assists the spread of HCV ...
    ... U.S. Department of Energy Joint Genome Institute (DOE JGI) ... (Glycine max) genetic code, making it widely available to ... one of the world,s most valuable plant commodities. ... world,s edible protein, but also is an emerging feedstock ...
    ... DECEMBER 8, 2008 Animal feeding operations are an ... and carbon dioxideknown greenhouse gases. Recent inventories suggest ... global methane emissions. As a consequence, greenhouse gas ... the development and sustainability of animal production and ...
    Cached Biology News:Leeds research points to new therapy for hepatitis C treatment 2DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Oil spray reduces greenhouse gas emissions from pig finishing barns 2
    HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    ... peptide transporter 2 (APT2) ... transporter PSF2) (Peptide supply ... transporter involved in antigen ... Antigen: ...
    Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
    Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
    Biology Products: